MediciNova, Inc.
MNOV · Price history
Price at last available close
$1.47
−$0.45 (-23.44%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About MediciNova, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction.
How they make money
MediciNova is a clinical-stage biopharmaceutical company that focuses on the development, in-licensing, and out-licensing of novel small-molecule therapeutics. The company does not currently generate revenue from product sales and relies on capital raises and potential future licensing or milestone payments to fund its research and development operations.
Products & services
MediciNova is developing a pipeline of drug candidates including MN-166 (ibudilast) for neurological and respiratory conditions, and MN-001 (tipelukast) for fibrotic and inflammatory diseases.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companies (for potential licensing)Source
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and manage development activities.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
29
Poor
Financial Strength
50
Business Quality / Moat
0
Management
40
Growth Quality
21
Risk / Durability
33
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
42
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
51/100
Building Historical Record
Model Score 51/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for MNOV
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MNOV maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can MNOV fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is MNOV likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for MNOV to reach sustainable profitability?
- •What future growth or profitability would be needed to justify MNOV's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
42
Market Cap
$72.4M
P/E Ratio
-8.2
EPS
$-0.22
52-Week High
$3.90
52-Week Low
$1.17
Beta
0.63
Analyst Target
$6.00
Shares Outstanding
49.1M
Total Revenue
$920K
Total Debt
$117K
Dividend
No current dividend
Liquidation Value / Share
$0.76
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on MNOV.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Diversified pipeline of clinical-stage drug candidates.
- +Experienced management team in drug development and licensing.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and uncertainty regarding future profitability.
- −Dependence on the success of clinical trials and regulatory approval processes.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
25
Oct 1, 2026
Change
-0.1
points
Current Score
25
Oct 5, 2026
Category Changes
MNOV decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
30
Projected Change
+5.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.47
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -59.0%
Revenue changed sharply from 2023 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $920K | $410K | $0.00 | $1.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $577K | $379K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $343K | $31K | $0.00 | $1.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $1.27B | $7.2M | $7.2M | $5.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.60B | $6.2M | $5.5M | $5.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $12.2M | $13.3M | $12.7M | $10.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$10.9M | -$12.0M | -$11.0M | -$8.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$11.9M | -$13.3M | -$12.7M | -$9.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$10.7M | -$12.0M | -$11.0M | -$8.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $6K | $6K | $6K | $3K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$10.8M | -$12.0M | -$11.0M | -$8.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.22 | $-0.24 | $-0.23 | $-0.17 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 49.22M | 49.06M | 49.05M | 49.05M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 49.22M | 49.06M | 49.05M | 49.05M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$458439
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.05
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-61.2%
Cash Change
-25.8%
Margin Change
+1933.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 240.6%. EPS declined 25.3%. Cash declined 25.8%. Total debt declined 61.2%. Net income margin improved by 1933.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
Rumor Mill · MNOV
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial